Viking Therapeutics (VKTX) just dropped a bombshell: their Phase 2 trial for the oral weight-loss pill VK2735 showed strong results—but also a massive dropout rate due to side effects like nausea and vomiting. Investors reacted fast, sending the stock down over 40% in a single day.In this episode of Ticker Shock, we break down:The science behind VK2735’s weight-loss resultsWhy the dropout rate is a red flag for future revenueThe math behind Viking’s projected earnings collapseWhat this means for biotech investors and the obesity drug race📉 Is Viking still a “Buy”? Or is this a speculative trap?🔔 Subscribe for more market deep dives and hit the bell so you never miss a shockwave.